Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized, Multiple-Dose, Two-Treatment, Two-Period, Two-Sequence, Crossover Study to Evaluate the Comparative Bioavailability of PrimeC (Ciprofloxacin and Celecoxib) Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Next Previous
Trial Profile

An Open Label, Randomized, Multiple-Dose, Two-Treatment, Two-Period, Two-Sequence, Crossover Study to Evaluate the Comparative Bioavailability of PrimeC (Ciprofloxacin and Celecoxib) Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Celecoxib/ciprofloxacin (Primary) ; Ciprofloxacin (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors NeuroSense Therapeutics

Most Recent Events

  • 05 Feb 2023 Status changed from active, no longer recruiting to completed.
  • 28 Sep 2022 According to a NeuroSense Therapeutics media release, data from the multi-dose PK and PARADIGM studies, will assist the company in designing a pivotal Phase III trial of PrimeC for the treatment of ALS in alignment with U.S. Food and Drug Administration (FDA) requirements.
  • 28 Sep 2022 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top